Evidence map›Paper›PMID 24384893›Full record

ArticleHeart and vessels2015

Successful percutaneous transluminal angioplasty for the treatment of renovascular hypertension with an atrophic kidney.

Keisuke Maruyama, Junko Chinda, Maki Kabara, Naoki Nakagawa, Takayuki Fujino, Toshiharu Takeuchi, Naoyuki Hasebe

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Heart and vessels, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Selective venous sampling for secondary hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Review
  2. Article
  3. Kidney enlargement effect of angioplasty for nonatherosclerotic renovascular disease: reversibility of ischemic kidney.Hypertension research : official journal of the Japanese Society of Hypertension · 2020
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Keisuke MaruyamaDivision of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Midorigaoka-higashi 2-1-1-1, Asahikawa, Japan, maru824@asahikawa-med.ac.jp.
Junko Chinda
Maki Kabara
Naoki Nakagawa
Takayuki Fujino
Toshiharu Takeuchi
Naoyuki Hasebe
Asahikawa Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renovascular hypertension is an important cause of secondary hypertension. We present the case of a 61-year-old man with renovascular hypertension caused by chronic total occlusion of the left renal artery resulting in an atrophic kidney. Although renography indicated almost no residual function of the left kidney, renal vein sampling showed a significant increase of renin secretion in the left kidney. The endocrine function of the left kidney was believed to be preserved; thus, we performed percutaneous transluminal renal angioplasty with stent placement. After the procedure, the patient's blood pressure decreased gradually to within the normal range without adverse events. The laboratory data on endocrine function and the renography findings drastically improved. Percutaneous transluminal renal angioplasty is a promising therapeutic procedure for renovascular hypertension with an atrophic kidney.

Indexed as

Angioplasty, BalloonAngiography, Digital SubtractionAtrophyHumansHypertension, RenovascularKidneyKidney Function TestsMaleMiddle AgedMultidetector Computed TomographyRenal Artery ObstructionStentsTreatment Outcome

Identifiers

PMID24384893
PMCPMC4352654
OpenAlexW2057550706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.